World Health Organization

Marburg virus – therapeutics prioritisation

Marco Cavaleri
21 January 2025

R&DBlueprint
Powering research to prevent epidemics

Prioritization of candidate treatments to be included in a randomized clinical trial

Product (Developer)	Type	Summary of Evidence	Availability	Recommendations
MBP091	Single monoclonal human Immunoglobulin G Type 1 (IgG1) antibody (MBP091) against the Marburg virus glycoprotein	**NHP Challenge:** This product has reported efficacy in non-human primate (NHP) challenge studies against Marburg virus disease. **Safety in Humans:** Safety data from the first human study is available. BP091 was well tolerated. No SAEs or grade 3 AEs reported. **Clinical Efficacy in Humans:** No clinical efficacy data against Marburg virus disease is available. Currently being developed under FDA's Animal Rule regulatory pathway	Doses available.	mBP091 is recommended for inclusion in the RCT for evaluation as both a monotherapy and combination therapy.
Remdesivir (**Gilead**)	Antiviral (AV)	**NHP Challenge:** This product has been reported to be effective against Marburg virus disease. Approval is being sought via the animal rule.	The product is commercially available in large amounts.	Remdesivir is recommended for inclusion in the RCT for evaluation as both monotherapy and combination therapy.

World Health Organization

To be considered for inclusion in the Core Protocol for filovirus treatment

As new candidates emerge, new consultations will take place

R&DBlueprint
Powering research to prevent epidemics